清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Asundexian versus Apixaban in Patients with Atrial Fibrillation

阿哌沙班 医学 心房颤动 冲程(发动机) 内科学 危险系数 栓塞 抗凝剂 肾脏疾病 心脏病学 置信区间 外科 拜瑞妥 华法林 机械工程 工程类
作者
Jonathan P. Piccini,Manesh R. Patel,Jan Steffel,Keith C. Ferdinand,Isabelle C. Van Gelder,Andrea M. Russo,Chang-Sheng Ma,Shaun G. Goodman,Jonas Oldgren,Christopher Hammett,Renato D. Lópes,Masaharu Akao,Raffaele De Caterina,Paulus Kirchhof,Diana A. Gorog,Martin E W Hemels,Michiel Rienstra,W. Schuyler Jones,Josephine Harrington,Gregory Y.H. Lip
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:392 (1): 23-32 被引量:150
标识
DOI:10.1056/nejmoa2407105
摘要

BACKGROUND: Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding. METHODS: In a phase 3, international, double-blind trial, we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban. The primary efficacy objective was to determine whether asundexian is at least noninferior to apixaban for the prevention of stroke or systemic embolism. The primary safety objective was to determine whether asundexian is superior to apixaban with respect to major bleeding events. RESULTS: -VASc score (range, 0 to 9, with higher scores indicating a greater risk of stroke) was 4.3±1.3. The trial was stopped prematurely at the recommendation of the independent data monitoring committee. Stroke or systemic embolism occurred in 98 patients (1.3%) assigned to receive asundexian and in 26 (0.4%) assigned to receive apixaban (hazard ratio, 3.79; 95% confidence interval [CI], 2.46 to 5.83). Major bleeding occurred in 17 patients (0.2%) who received asundexian and in 53 (0.7%) who received apixaban (hazard ratio, 0.32; 95% CI, 0.18 to 0.55). The incidence of any adverse event appeared to be similar in the two groups. CONCLUSIONS: Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, 2022-000758-28.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
zjkzh完成签到 ,获得积分10
6秒前
10秒前
junzzz完成签到 ,获得积分10
18秒前
19秒前
见物思理完成签到 ,获得积分10
24秒前
如懿完成签到,获得积分10
24秒前
如意亦瑶完成签到,获得积分10
26秒前
27秒前
35秒前
拼搏幻柏完成签到,获得积分10
36秒前
YNILY完成签到 ,获得积分10
41秒前
43秒前
岳晓燕完成签到 ,获得积分10
46秒前
52秒前
56秒前
luoqin完成签到 ,获得积分10
59秒前
1分钟前
怼怼完成签到 ,获得积分10
1分钟前
1分钟前
机智的妙芹完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
zxdzaz完成签到 ,获得积分10
1分钟前
成就小蜜蜂完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
夕阳下仰望完成签到 ,获得积分10
1分钟前
1分钟前
典雅涵瑶发布了新的文献求助10
1分钟前
稳重的秋天完成签到,获得积分10
1分钟前
1分钟前
留胡子的翠容完成签到,获得积分10
1分钟前
1分钟前
典雅涵瑶完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346